| General Information | |
|---|---|
| ZINC ID | ZINC000072110849 |
| Molecular Weight (Da) | 494 |
| SMILES | C[C@@H](NC(=O)C1(NC(=O)c2cncc(O)c2)CC1)c1ccc(-n2nc(Cl)c3ccccc32)cc1F |
| Molecular Formula | C25Cl1F1N5O3 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 129.155 |
| HBA | 5 |
| HBD | 3 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 35 |
| LogP | 3.375 |
| Activity (Ki) in nM | 0.302 |
| Polar Surface Area (PSA) | 109.14 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.029 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 21 |
| Fraction csp3 | 0.2 |
| Ilogp | 2.69 |
| Xlogp3 | 3.73 |
| Wlogp | 4.09 |
| Mlogp | 2.6 |
| Silicos-it log p | 3.83 |
| Consensus log p | 3.39 |
| Esol log s | -5.17 |
| Esol solubility (mg/ml) | 0.00335 |
| Esol solubility (mol/l) | 0.00000679 |
| Esol class | Moderately |
| Ali log s | -5.71 |
| Ali solubility (mg/ml) | 0.000955 |
| Ali solubility (mol/l) | 0.00000193 |
| Ali class | Moderately |
| Silicos-it logsw | -8.15 |
| Silicos-it solubility (mg/ml) | 0.00000349 |
| Silicos-it solubility (mol/l) | 7.06E-09 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -6.66 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 0 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 3 |
| Synthetic accessibility | 3.53 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -4.9 |
| Logd | 3.402 |
| Logp | 3.599 |
| F (20%) | 0.001 |
| F (30%) | 0.002 |
| Mdck | - |
| Ppb | 94.53% |
| Vdss | 1.658 |
| Fu | 2.87% |
| Cyp1a2-inh | 0.468 |
| Cyp1a2-sub | 0.147 |
| Cyp2c19-inh | 0.709 |
| Cyp2c19-sub | 0.161 |
| Cl | 1.926 |
| T12 | 0.131 |
| H-ht | 0.79 |
| Dili | 0.975 |
| Roa | 0.403 |
| Fdamdd | 0.956 |
| Skinsen | 0.241 |
| Ec | 0.003 |
| Ei | 0.008 |
| Respiratory | 0.268 |
| Bcf | 0.431 |
| Igc50 | 3.355 |
| Lc50 | 4.632 |
| Lc50dm | 5.194 |
| Nr-ar | 0.024 |
| Nr-ar-lbd | 0.007 |
| Nr-ahr | 0.897 |
| Nr-aromatase | 0.822 |
| Nr-er | 0.625 |
| Nr-er-lbd | 0.018 |
| Nr-ppar-gamma | 0.161 |
| Sr-are | 0.867 |
| Sr-atad5 | 0.554 |
| Sr-hse | 0.305 |
| Sr-mmp | 0.813 |
| Sr-p53 | 0.921 |
| Vol | 469.169 |
| Dense | 1.051 |
| Flex | 0.296 |
| Nstereo | 1 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 2 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | - |
| Toxicophores | 2 |
| Qed | 0.375 |
| Synth | 3.28 |
| Fsp3 | 0.2 |
| Mce-18 | 96 |
| Natural product-likeness | -1.35 |
| Alarm nmr | 1 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |